216309-28-3

Usage

Uses

Used in Organic Synthesis:
5-((Trimethylsilyl)ethynyl)pyrimidine is used as a building block in organic synthesis for its unique reactivity and properties. It serves as a crucial component in the creation of complex organic molecules, facilitating the development of novel chemical entities with potential applications in various fields.
Used in Pharmaceutical Industry:
5-((Trimethylsilyl)ethynyl)pyrimidine is used as a precursor in the preparation of pharmaceuticals for its ability to contribute to the synthesis of biologically active molecules. Its presence in the molecular structure can enhance the pharmacological properties of the resulting compounds, leading to the development of new drugs with improved efficacy and safety profiles.
Used in Agrochemical Industry:
5-((Trimethylsilyl)ethynyl)pyrimidine is used as a precursor in the development of agrochemicals, such as pesticides and herbicides. Its unique structure allows for the creation of molecules with enhanced pesticidal or herbicidal activity, contributing to more effective and environmentally friendly agricultural solutions.
Used in Medicinal Chemistry Research:
5-((Trimethylsilyl)ethynyl)pyrimidine is utilized as a key intermediate in the synthesis of biologically active molecules for medicinal chemistry research. Its unique properties and reactivity make it an essential component in the exploration of new chemical space and the discovery of innovative therapeutic agents.

InChI:InChI=1/C9H12N2Si/c1-12(2,3)5-4-9-6-10-8-11-7-9/h6-8H,1-3H3

Upstream product

• 4595-59-9 5-bromopyrimidine 
• 1066-54-2 trimethylsilylacetylene 
• 31462-58-5 5-iodopyrimidine 

Downstream Products

• 153286-94-3 5-ethynylpyrimidine 
• 1428445-71-9 C₂₅H₁₈F₃N₅O 

Relevant academic research and scientific papers

Synthesis of Distorted Nitrogen-Doped Nanographenes by Partially Oxidative Cyclodehydrogenation Reaction

A series of partially fused N-doped nanographenes (2–4) are synthesized via the oxidative cyclodehydrogenation of oligoaryl-substituted dibenzo[e,l]pyrene (1), and five, six, and seven new C?C bonds are formed, respectively, implying stepwise C?C bond fusion and extended π-conjugation. Single-crystal X-ray diffraction analysis of compound 4 a revealed that the presence of sterically demanding groups hindered the formation of planar and fully fused nanographene in the oxidative cyclodehydrogenation reaction step. Optical study of compounds 2 to 4 showed that extended π-conjugation leads to a regular stepwise bathochromic shift in the absorption and emission spectra. Furthermore, the HOMO–LUMO gaps of these compounds exhibit a decrease as C?C bond formation proceeds. Thus, the optoelectronic properties of nanographenes are highly dependent on the formation of new C?C bonds in the molecular skeleton.

Design and characterization of a heterocyclic electrophilic fragment library for the discovery of cysteine-targeted covalent inhibitors

A fragment library of electrophilic small heterocycles was characterized through cysteine-reactivity and aqueous stability tests that suggested their potential as covalent warheads. The analysis of theoretical and experimental descriptors revealed correlations between the electronic properties of the heterocyclic cores and their reactivity against GSH that are helpful in identifying suitable fragments for cysteines with specific nucleophilicity. The most important advantage of these fragments is that they show only minimal structural differences from non-electrophilic counterparts. Therefore, they could be used effectively in the design of targeted covalent inhibitors with minimal influence on key non-covalent interactions.

Direct synthesis of α-trifluoromethyl ketone from (hetero)arylacetylene: Design, intermediate trapping, and mechanistic investigations

Regioselective addition across the alkynes has been achieved in a silver-catalyzed protocol utilizing Langlois reagent (CF3SO2Na) and molecular O2 to access medicinally active α-trifluoromethyl ketone compounds. This metho

Rapid discovery of a novel series of Abl kinase inhibitors by application of an integrated microfluidic synthesis and screening platform

Drug discovery faces economic and scientific imperatives to deliver lead molecules rapidly and efficiently. Using traditional paradigms the molecular design, synthesis, and screening loops enforce a significant time delay leading to inefficient use of data in the iterative molecular design process. Here, we report the application of a flow technology platform integrating the key elements of structure-activity relationship (SAR) generation to the discovery of novel Abl kinase inhibitors. The platform utilizes flow chemistry for rapid in-line synthesis, automated purification, and analysis coupled with bioassay. The combination of activity prediction using Random-Forest regression with chemical space sampling algorithms allows the construction of an activity model that refines itself after every iteration of synthesis and biological result. Within just 21 compounds, the automated process identified a novel template and hinge binding motif with pIC50 > 8 against Abl kinase - both wild type and clinically relevant mutants. Integrated microfluidic synthesis and screening coupled with machine learning design have the potential to greatly reduce the time and cost of drug discovery within the hit-to-lead and lead optimization phases.

Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant

Ponatinib (AP24534) was previously identified as a pan-BCR-ABL inhibitor that potently inhibits the T315I gatekeeper mutant, and has advanced into clinical development for the treatment of refractory or resistant CML. In this study, we explored a novel series of five and six membered monocycles as alternate hinge-binding templates to replace the 6,5-fused imidazopyridazine core of ponatinib. Like ponatinib, these monocycles are tethered to pendant toluanilides via an ethynyl linker. Several compounds in this series displayed excellent in vitro potency against both native BCR-ABL and the T315I mutant. Notably, a subset of inhibitors exhibited desirable PK and were orally active in a mouse model of T315I-driven CML.

5-PHENYL-NICOTINAMIDE DERIVATIVES

The present invention relates to compounds of the formula wherein R1 to R8 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of

Synthesis of meso-extended tetraarylporphyrins

(Chemical Equation Presented) The synthesis of five new meso-tetraarylporphyrins having pyridine, pyrimidine, or nitrile groups extending tetragonally via alkynyl linkages from the para positions is described. The radial extension is nearly double that of

Novel 3-phenylprop-2-ynylamines as inhibitors of mammalian squalene epoxidase.

The synthesis of a novel series of 3-phenylprop-2-ynylamines as selective mammalian squalene epoxidase inhibitors is described. Structure activity relationship studies led to the discovery of compound 19, 1-[3-(3,5-dichlorophenyl)-prop-2-ynyl]-3- methylpiperidine hydrochloride with an IC50 of 2.8 +/- 0.6 microM against rat liver squalene epoxidase. Against 23 strains of fungal squalene epoxidase compound 19 was found to be inactive.

TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS

This application relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and its use as an inhibitor of the NK-1 subtype of tachykinin receptors, as well as a process for its preparation and intermediates therefor. (I) wherein: D is a C1-C3 alkane-diyl; R1 is phenyl, which is optionally substituted with one to three substitutents indpendently selected from the group consisting of halo, C1-C4 alkyl, C1-C4 alkoxy, cyano, difluoromethyl, trifluoromethyl, and trifluoromethoxy; R4 is a radical selected from the group consisting of: (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH)

Palladium-catalyzed cross-alkynylation of aryl bromides by sodium tetraalkynylaluminates

Sodium tetraalkynylaluminates (1-4), prepared from NaAlH4 and terminal alkynes, cross-couple with aryl bromides in the presence of Pd(0) and Pd(II) catalysts. The reactions take place in boiling THF or DME. The process is applicable to both hom